1
Douglas J Allen, Kirk W Johnson, Robert S Nevin: Hydrophilic polyurethane membranes for electrochemical glucose sensors. Eli Lilly and Company, Woodward Emhardt Naughton Moriarty & McNett, June 21, 1994: US05322063 (730 worldwide citation)

Homogeneous membranes permeable to oxygen and glucose composed of hydrophilic polyurethanes that are capable of absorbing from 10 to 50% of their dry weight of water. Variations in the composition of the hydrophilic polyurethanes make possible the fabrication of membranes in which the ratios of the ...


2
Douglas J Allen, Robert S Nevin: Acrylic copolymer membranes for biosensors. Eli Lilly and Company, Woodard Emhardt Naughton Moriarty & McNett, February 8, 1994: US05284140 (347 worldwide citation)

Homogeneous membranes are disclosed which are composed of acrylic copolymers and are capable of absorbing 10% to 50% of their dry weight of water. The copolymers include a hydrophilic component which comprises acrylic esters having a poly(ethylene oxide) substituent as part of the alcohol moiety. Th ...


3
Douglas J Allen, Robert S Nevin: Acrylic copolymer membranes for biosensors. Eli Lilly and Company, Woodard Emhardt Naughton Moriarty & McNett, December 19, 1995: US05476094 (85 worldwide citation)

Homogeneous membranes are disclosed which are composed of acrylic copolymers and are capable of absorbing 10% to 50% of their dry weight of water. The copolymers include a hydrophilic component which comprises acrylic esters having a poly(ethylene oxide) substituent as part of the alcohol moiety. Th ...


4
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly and Company, Nelsen L Lentz, Arleen Palmberg, September 9, 2003: US06617321 (3 worldwide citation)

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.


5
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly and Company, Nelson L Lentz, December 4, 2007: US07303764 (2 worldwide citation)

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.


6
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly And Company, May 20, 2004: US20040097489-A1

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.


7
Douglas J Allen, Kurt D Dekemper, Thomas H Ferguson, Stuart J Garvin, Linda C Murray, Norman D Brooks, Charles A Bunnell, Snehlata S Mascarenhas, Sharon L Shinkle, Barry A Hendriksen, David E Tupper, Manuel V Sanchez Felix: 2-methyl-thieno-benzodiazepine formulation. Eli Lilly And Company, February 6, 2003: US20030027816-A1

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.



Click the thumbnails below to visualize the patent trend.